Highlights the historical shift in heart failure management from relying on digitalis to utilizing vasodilating agents that reduce cardiac workload.
Answers are grounded in this paper and cite their sources.
May contextualize current vasodilator strategies in HF; leaves open updated syntheses incorporating recent trials.
Digitalis has always been the cornerstone of therapy for congestive heart failure. Although the benefits of other therapeutic measures are important, nevertheless, the primary aim in the treatment of congestive heart failure was to improve myocardial contractility using a digitalis glycoside. However, in recent years the management of congestive heart failure has taken a new and sophisticated direction. Therapeutic measures that reduce the work of the heart currently receive more attention than do drugs that improve myocardial contractility. Newer attitudes in management are evolving as a consequence of the successful results from treatment that influence the work load of the heart. Specifically, the focus is on vasodilating or unloading agents that reduce the work of the heart by decreasing cardiac preload and afterload.¹⁻²¹Selective vasodilation has proved to be the decisive factor in reversing severe congestive heart failure refractory to all other therapy. The emergence of the unloading agents
No takes yet. Share an insight, caveat, or question.
Louis Lemberg (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: